Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Arctic Bioscience are pleased to announce that we have been invited to present at the Glaucoma 360 New Horizons Forum in San Francisco on January 30th 2026, in the session `The Perfect Dose: Innovating Drugs and Drug Delivery'.
Our Medical Director, Runhild Gammelsæter, will be presenting our latest pipeline project, ABS403, with the aim to promote resolution of inflammation and support neuroprotection in glaucoma. This eye disease does not currently have a cure and leads to blindness.
The project was initiated based on encouraging clinical signals from a pilot study in glaucoma (POAG).
As we prepare for the next stages, we are actively seeking partners and investors to join us in advancing ABS403 into further clinical development.
Read more about the event: https://glaucoma360.org/
Read more about the promising pilot trial by Luo et al: https://doi.org/10.1007/s10792-025-03693-1